🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Solventum Corporation SOLV SPX

Healthcare · Medical Instruments & Supplies · United States
https://www.solventum.com

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.

READ MORE ›
$74.95
+2.54% 1Y

Market & Price

Market Cap
$12.98B
Current Price
$74.95
High / Low (52W)
$86.14 / $62.49
Beta
0.66

Valuation

Stock P/E
9.17
Industry PE
23.65
Forward P/E
10.64
PEG Ratio
1.22
Book Value
$29.10
Price to Book
2.58
P/S
1.57
EV/EBITDA
15.76
Dividend Yield
-

Profitability & Returns

ROCE
18.46%
ROE
34.79%
ROA
2.75%
Profit Margin
17.33%
Op Margin
5.58%
EPS (Latest Qtr)
$0.07
EPS (TTM)
$8.17

Balance Sheet & Liquidity

Debt/Equity
1.06
Quick Ratio
0.52
Current Ratio
1.07
Debt
$5.29B
Total Assets
$14.29B
Current Assets
$3.86B
Working Capital
$723.00M

Ownership

Promoter Holding
15.07%
Chg in Prom Hold
-
FII / Inst Holding
76.46%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$17.71B
Total Revenue (TTM)
$8.26B
EBITDA
$1.12B
Free Cash Flow
$378.50M
Operating Cash Flow
$151.00M
Shares Outstanding
173.17M
Gross Margin
53.65%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
0.79%
Profit 5Y
5.03%
Revenue (YoY)
-3.00%
Earnings (YoY)
-91.00%

PROS

  • Strong return on equity of 34.8%.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SOLV Solventum Corporation SPX 74.95 9.17 $12.98B - 18.46% 34.79% 0.79% 5.03%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 2.01B2.08B2.07B2.02B2.08B-2.07B2.16B2.10B2.00B2.01B
Cost of Revenue ------956.00M986.00M961.00M971.00M911.00M
Gross Profit 1.14B1.19B1.21B1.17B1.14B-1.11B1.18B1.14B1.03B1.09B
Operating Expenses ------962.00M961.00M963.00M934.00M1.02B
Operating Income 365.00M417.00M504.00M381.00M244.00M-152.00M214.00M172.00M93.00M79.00M
EBITDA ------271.00M328.00M1.72B226.00M213.00M
Interest Expense ------104.00M103.00M89.00M51.00M62.00M
Pretax Income ------38.00M103.00M1.51B58.00M16.00M
Tax Provision -------99.00M13.00M248.00M-5.00M3.00M
Net Income 293.00M321.00M460.00M237.00M89.00M-137.00M90.00M1.27B63.00M13.00M
Diluted EPS 1.701.862.661.370.51-0.780.517.220.360.07
R&D Expense 195.00M193.00M180.00M195.00M192.00M189.00M193.00M189.00M183.00M-189.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -8.13B8.20B8.25B8.32B
Cost of Revenue -3.44B3.50B3.66B3.87B
Gross Profit -4.70B4.69B4.59B4.45B
Operating Expenses -3.00B3.06B3.56B3.82B
Operating Income -1.69B1.64B1.04B632.00M
EBITDA -2.27B2.23B1.53B2.55B
Interest Expense -00367.00M347.00M
Pretax Income -1.69B1.67B605.00M1.71B
Tax Provision -349.00M321.00M127.00M157.00M
Net Income -1.34B1.35B479.00M1.56B
Diluted EPS -7.787.792.768.88
R&D Expense -767.00M758.00M775.00M739.00M

Compounded Sales Growth

5 Years:0.79%
1 Year:-3.00%

Compounded Profit Growth

5 Years:5.03%
1 Year:-91.00%

Stock Price Performance

1 Year:+2.54%
6 Months:-12.62%
3 Months:+1.01%
1 Month:+12.72%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -13.59B13.94B14.46B14.29B
Current Assets -2.23B2.52B3.25B3.86B
Cash & Equivalents -61.00M194.00M762.00M878.00M
Inventory -873.00M857.00M965.00M1.07B
Receivables -1.17B1.31B1.04B1.03B
Total Liabilities -1.85B2.28B11.50B9.24B
Current Liabilities -1.31B1.73B2.70B3.14B
Long Term Debt --8.30B7.81B5.04B
Total Debt --8.30B8.01B5.04B
Total Equity -11.74B11.67B2.96B5.05B
Shares Outstanding -172.71M172.71M172.79M173.49M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.68B1.92B1.19B369.00M
Investing Cash Flow --253.00M-230.00M-380.00M2.80B
Financing Cash Flow --1.46B-1.55B-240.00M-3.06B
Capital Expenditure --251.00M-290.00M-380.00M-379.00M
Free Cash Flow -1.43B1.62B805.00M-10.00M
Net Change in Cash --34.00M133.00M565.00M109.00M

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -57.7%57.3%55.6%53.5%
Operating Margin % -20.8%20.0%12.6%7.6%
Net Margin % -16.5%16.4%5.8%18.7%
ROE % -11.4%11.5%16.2%30.8%
ROCE % -13.8%13.4%8.8%5.7%

Shareholding Pattern

Insiders
15.07%
Institutions
76.46%
Public Float
90.03%

Top Institutional Holders

#Holder% HeldSharesValue
1 Independent Franchise Partners, LLP 9.09% 15.73M $1.18B
2 Blackrock Inc. 6.05% 10.48M $785.40M
3 Vanguard Capital Management LLC 5.54% 9.60M $719.67M
4 Trian Fund Management, LP 4.76% 8.24M $617.34M
5 State Street Corporation 3.70% 6.41M $480.24M
6 Vanguard Portfolio Management LLC 3.69% 6.39M $478.96M
7 Davis Selected Advisers 3.66% 6.33M $474.46M
8 Geode Capital Management, LLC 2.74% 4.75M $356.18M
9 Boston Partners 2.26% 3.91M $293.36M
10 Invesco Ltd. 2.19% 3.79M $284.05M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SOLV

MIT Technology Review hu, 28 May 2026

The Download: climate tech goes public and the AI Hype Index returns

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Climate tech companies are going public. What’s ne…

MIT Technology Review hu, 28 May 2026

Climate tech companies are going public. What’s next?

This year, there’s been a wave of notable energy companies going public via IPO in the US. The solar and battery company Solv Energy went public in February, to the tune of $6 billion. X-energy, which…

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks